CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 186 filers reported holding CHEMOCENTRYX INC in Q1 2021. The put-call ratio across all filers is 1.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $50,824,000 | +453.3% | 983,809 | +165.4% | 0.03% | +400.0% |
| Q2 2022 | $9,186,000 | -71.8% | 370,692 | -71.5% | 0.01% | -64.7% |
| Q1 2022 | $32,615,000 | -27.1% | 1,300,949 | +5.9% | 0.02% | -26.1% |
| Q4 2021 | $44,720,000 | +307.7% | 1,228,224 | +91.5% | 0.02% | +228.6% |
| Q3 2021 | $10,969,000 | +156.0% | 641,448 | +100.5% | 0.01% | +133.3% |
| Q2 2021 | $4,284,000 | +87.8% | 319,927 | +618.7% | 0.00% | +50.0% |
| Q1 2021 | $2,281,000 | -63.2% | 44,514 | -60.6% | 0.00% | -71.4% |
| Q3 2020 | $6,195,000 | -51.5% | 113,056 | -49.0% | 0.01% | -58.8% |
| Q2 2020 | $12,764,000 | -10.6% | 221,832 | -37.6% | 0.02% | -46.9% |
| Q1 2020 | $14,273,000 | -3.8% | 355,231 | -5.3% | 0.03% | +68.4% |
| Q4 2019 | $14,831,000 | +127.9% | 374,984 | -60.9% | 0.02% | +90.0% |
| Q3 2019 | $6,508,000 | +130.6% | 960,059 | +216.4% | 0.01% | +150.0% |
| Q2 2019 | $2,822,000 | +307.8% | 303,400 | +509.1% | 0.00% | +300.0% |
| Q1 2019 | $692,000 | +278.1% | 49,812 | +196.3% | 0.00% | – |
| Q4 2018 | $183,000 | -92.7% | 16,813 | -91.5% | 0.00% | -100.0% |
| Q3 2018 | $2,501,000 | -51.0% | 197,850 | -49.0% | 0.00% | -57.1% |
| Q2 2018 | $5,108,000 | +15.9% | 387,875 | +19.7% | 0.01% | +16.7% |
| Q1 2018 | $4,408,000 | +189.6% | 324,112 | +26.7% | 0.01% | +200.0% |
| Q4 2017 | $1,522,000 | -6.2% | 255,831 | +16.9% | 0.00% | 0.0% |
| Q3 2017 | $1,623,000 | +43.5% | 218,762 | +81.0% | 0.00% | 0.0% |
| Q2 2017 | $1,131,000 | +1.3% | 120,879 | -21.1% | 0.00% | 0.0% |
| Q1 2017 | $1,116,000 | +232.1% | 153,248 | +237.9% | 0.00% | +100.0% |
| Q4 2016 | $336,000 | +253.7% | 45,358 | +189.7% | 0.00% | – |
| Q3 2016 | $95,000 | +61.0% | 15,655 | +18.9% | 0.00% | – |
| Q2 2016 | $59,000 | -83.9% | 13,172 | -78.3% | 0.00% | -100.0% |
| Q3 2015 | $367,000 | -38.2% | 60,718 | -15.8% | 0.00% | 0.0% |
| Q2 2015 | $594,000 | -36.4% | 72,146 | -41.7% | 0.00% | -50.0% |
| Q1 2015 | $934,000 | -65.4% | 123,653 | -68.7% | 0.00% | -66.7% |
| Q4 2014 | $2,698,000 | +2167.2% | 395,000 | +1396.0% | 0.01% | – |
| Q3 2014 | $119,000 | -70.6% | 26,403 | -56.8% | 0.00% | -100.0% |
| Q1 2014 | $405,000 | +335.5% | 61,111 | +279.6% | 0.00% | – |
| Q4 2013 | $93,000 | -94.8% | 16,100 | -95.0% | 0.00% | -100.0% |
| Q3 2013 | $1,775,000 | -56.4% | 319,203 | +10.9% | 0.01% | -50.0% |
| Q2 2013 | $4,068,000 | – | 287,721 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |